Cargando…

Preclinical immunogenicity assessment of a cell-based inactivated whole-virion H5N1 influenza vaccine

In influenza vaccine development, Madin–Darby canine kidney (MDCK) cells provide multiple advantages, including large-scale production and egg independence. Several cell-based influenza vaccines have been approved worldwide. We cultured H5N1 virus in a serum-free MDCK cell suspension. The harvested...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Zhegang, Jiang, Zheng, Deng, Tao, Zhang, Jiayou, Liu, Bo, Liu, Jing, Qiu, Ran, Zhang, Qingmei, Li, Xuedan, Nian, Xuanxuan, Hong, Yue, Li, Fang, Peng, Feixia, Zhao, Wei, Xia, Zhiwu, Huang, Shihe, Liang, Shuyan, Chen, Jinhua, Li, Changgui, Yang, Xiaoming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	De Gruyter 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518664/ https://www.ncbi.nlm.nih.gov/pubmed/36249527 http://dx.doi.org/10.1515/biol-2022-0478

Ejemplares similares

The Epidemiology of Influenza and the Associated Vaccines Development in China: A Review
por: Zhang, Jiayou, et al.
Publicado: (2022)

Viral Vector-Based Gene Therapy
por: Li, Xuedan, et al.
Publicado: (2023)

Safety and immunogenicity of a quadrivalent, inactivated, split-virion influenza vaccine (IIV4-W) in healthy people aged 3-60 years: a phase III randomized clinical noninferiority trial
por: Huang, Xiaoyuan, et al.
Publicado: (2022)

Development of Nasal Vaccines and the Associated Challenges
por: Nian, Xuanxuan, et al.
Publicado: (2022)

TRAF3 deficiency in MDCK cells improved sensitivity to the influenza A virus
por: Le, Yang, et al.
Publicado: (2023)

AddaVax Formulated with PolyI:C as a Potential Adjuvant of MDCK-based Influenza Vaccine Enhances Local, Cellular, and Antibody Protective Immune Response in Mice
por: Nian, Xuanxuan, et al.
Publicado: (2021)

Liposome and QS-21 Combined Adjuvant Induces theHumoral and Cellular Responses of Acellular Pertussis Vaccine in a Mice Model
por: Yang, Baifeng, et al.
Publicado: (2023)

Immunogenicity and safety of an inactivated enterovirus 71 vaccine coadministered with trivalent split-virion inactivated influenza vaccine: A phase 4, multicenter, randomized, controlled trial in China
por: Chen, Yaping, et al.
Publicado: (2022)

Long-Term Immunogenicity Studies of Formalin-Inactivated Enterovirus 71 Whole-Virion Vaccine in Macaques
por: Liu, Chia-Chyi, et al.
Publicado: (2014)

Immunogenicity Studies of Bivalent Inactivated Virions of EV71/CVA16 Formulated with Submicron Emulsion Systems
por: Lin, Chih-Wei, et al.
Publicado: (2014)

Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine
por: Montalban, Cecilia, et al.
Publicado: (2017)

Safety and immunogenicity of rabies vaccine (PVRV-WIBP) in healthy Chinese aged 10–50 years old: Randomized, blinded, parallel controlled phase III clinical study
por: Huang, Xiaoyuan, et al.
Publicado: (2023)

Immunogenicity and safety of an intramuscular split-virion quadrivalent inactivated influenza vaccine in individuals aged ≥ 6 months in India
por: Agarkhedkar, Sharad, et al.
Publicado: (2019)

Safety and immunogenicity of a quadrivalent influenza vaccine in adults aged 60 years or above: a phase III randomized controlled clinical study
por: Fan, Renfeng, et al.
Publicado: (2021)

Preclinical Evaluation of the Immunogenicity and Safety of an Inactivated Enterovirus 71 Candidate Vaccine
por: Hwa, Shi-Hsia, et al.
Publicado: (2013)

Independent Protection and Influence of the Spike-Specific Antibody Response of SARS-CoV-2 Nucleocapsid Protein (N) in Whole-Virion Vaccines
por: Yang, Huijie, et al.
Publicado: (2023)

Immunogenicity and Safety of an Inactivated SARS-CoV-2 Vaccine: Preclinical Studies
por: Kandeil, Ahmed, et al.
Publicado: (2021)

Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial
por: Xia, Shengli, et al.
Publicado: (2022)

Low immunogenicity of whole virion, verocell-derived, inactivated, pandemic influenza H1N1 vaccine in HIV-infected patients
por: Lagler, H, et al.
Publicado: (2010)

Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS- CoV-2 vaccine candidates in the Syrian hamster model
por: Mohandas, Sreelekshmy, et al.
Publicado: (2021)

Safety and Immunogenicity of Inactivated Whole Virion COVID-19 Vaccine CoviVac in Clinical Trials in 18–60 and 60+ Age Cohorts
por: Gordeychuk, Ilya V., et al.
Publicado: (2023)

Inactivated or damaged? Comparing the effect of inactivation methods on influenza virions to optimize vaccine production
por: Herrera-Rodriguez, José, et al.
Publicado: (2019)

RF_phage virion: Classification of phage virion proteins with a random forest model
por: Zhang, Yanqin, et al.
Publicado: (2023)

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
por: Guo, Wanshen, et al.
Publicado: (2021)

Corrigendum: RF_phage virion: classification of phage virion proteins with a random forest model
por: Zhang, Yanqin, et al.
Publicado: (2023)

Immunogenicity and safety of the quadrivalent inactivated split-virion influenza vaccine in populations aged ≥ 3 years: A phase 3, randomized, double-blind, non-inferiority clinical trial
por: Chen, Jianmin, et al.
Publicado: (2023)

Immunogenicity of SARS inactivated vaccine in BALB/c mice
por: Xiong, Sheng, et al.
Publicado: (2004)

Metabolomics profiling reveals differences in proliferation between tumorigenic and non-tumorigenic Madin-Darby canine kidney (MDCK) cells
por: Sun, Na, et al.
Publicado: (2023)

Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial
por: Chen, Haiping, et al.
Publicado: (2022)

Effectiveness, immunogenicity, and safety of influenza vaccines with MF59 adjuvant in healthy people of different age groups: A systematic review and meta-analysis
por: Yang, Jing, et al.
Publicado: (2020)

Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China
por: Hu, Yuemei, et al.
Publicado: (2019)

Immunogenicity of influenza vaccine in elderly people: a systematic review and meta-analysis of randomized controlled trials, and its association with real-world effectiveness
por: Meng, Ziyan, et al.
Publicado: (2020)

Complexes of Zinc With Picolinic and Aspartic Acids Inactivate Free Varicella-Zoster Virions
por: Shishkov, S., et al.
Publicado: (1996)

A promising inactivated whole-virion SARS-CoV-2 vaccine
por: Isakova-Sivak, Irina, et al.
Publicado: (2021)

Large-Scale Preparation of UV-Inactivated SARS Coronavirus Virions for Vaccine Antigen
por: Tsunetsugu-Yokota, Yasuko
Publicado: (2007)

Effect of Inactivation Methods on SARS-CoV-2 Virion Protein and Structure
por: Loveday, Emma K., et al.
Publicado: (2021)

The Murine Gammaherpesvirus-68 gp150 Acts as an Immunogenic Decoy to Limit Virion Neutralization
por: Gillet, Laurent, et al.
Publicado: (2007)

Immunogenicity of inactivated rotavirus in rhesus monkey, and assessment of immunologic mechanisms
por: Zhou, Yan, et al.
Publicado: (2023)

Biochemical and antigenic characterization of the structural proteins and their post-translational modifications in purified SARS-CoV-2 virions of an inactivated vaccine candidate
por: Zhang, Xiao-Yu, et al.
Publicado: (2020)

Exploring the inside details of virions by electron microscopy
por: Liu, Zheng, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_3c5jrmeev45msiasog52n6jofk